Abstract
Abstract
Background
Cushing’s syndrome (CS) is a rare clinical condition caused by excessive cortisol secretion from adrenal glands. CS is associated with increased mortality and morbidity; therefore, a prompt diagnosis and an effective therapeutic approach are strongly necessary to improve the patient’s clinical management. The first-line treatment for CS is surgery, while medical treatment has historically played a minor role. However, thanks to the availability of novel compounds, the possibility of improving hypercortisolism control using different drug combinations emerged.
Purpose
No absolute recommendations are available to guide the therapeutic choice for patients with CS and, consequently, the awareness of unmet needs in CS management is growing. Although new data from clinical trials are needed to better define the most appropriate management of CS, an expert consensus approach can help define unmet needs and optimize the current CS management and treatment.
Methods
Twenty-seven endocrinologists from 12 Italian regions, working among the main Italian referral centers for hospital endocrinology where they take care of CS patients, were involved in a consensus process and used the Delphi method to reach an agreement on 24 statements about managing CS patients.
Results
In total, 18 statements reached a consensus. Some relevant unmet needs in the management of CS were reported, mainly related to the lack of a pharmacological treatment successful for the majority of patients.
Conclusion
While acknowledging the difficulty in achieving complete disease control, a significant change in CS management requires the availability of medical treatment with improved efficacy and safety over available therapeutic options at the time of the current study.
Funder
Recordati Rare Diseases
Università degli Studi di Napoli Federico II
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference71 articles.
1. Pivonello R, De Martino MC, De Leo M, Simeoli C, Colao A (2017) Cushing’s disease: the burden of illness. Endocrine 56(1):10–18
2. Orphanet Report Series: Rare Diseases Collection. Prevalence and incidence of rare diseases: Bibliographic data. Prevalence, incidence, or number of published cases listed by diseases (in alphabetical order). 2020. https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf. Accessed 1 Jan 2022.
3. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY (2022) Clinical biology of the pituitary adenoma. Endocr Rev 8:bnac010. https://doi.org/10.1210/endrev/bnac010
4. Hayes AR, Grossman AB (2018) The ectopic adrenocorticotropic hormone syndrome: rarely easy, always challenging. Endocrinol Metab Clin North Am 47(2):409–425. https://doi.org/10.1016/j.ecl.2018.01.005
5. Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, Barba L, Negri M, De Angelis C, Colao A (2020) Medical treatment of Cushing’s disease: an overview of the current and recent clinical trials. Front Endocrinol (Lausanne) 11:648. https://doi.org/10.3389/fendo.2020.00648